News
Flexible, Modular Tech Platform Overcomes Conventional ADC Toxicity and Resistance Limits

Flexible, Modular Tech Platform Overcomes Conventional ADC Toxicity and Resistance Limits

02 Jan,2025

MORE
FDA Greenlights PrimeLink Bio’s Clinical Trial of PLB-002

FDA Greenlights PrimeLink Bio’s Clinical Trial of PLB-002

09 Oct,2025

MORE
Dual-Payload ADCs: A New Chapter in Cancer Therapy

Dual-Payload ADCs: A New Chapter in Cancer Therapy

10 Mar,2025

MORE
PLB-002, PrimeLink Bio’s Anti-Claudin 6 ADC, Receives IND Acceptance from NMPA and FDA

PLB-002, PrimeLink Bio’s Anti-Claudin 6 ADC, Receives IND Acceptance from NMPA and FDA

08 Sep,2025

MORE
Breaking: PrimeLink Bio Named 2025 Shenzhen Seed Unicorn

Breaking: PrimeLink Bio Named 2025 Shenzhen Seed Unicorn

31 Jul,2025

MORE
PrimeLink to Present Preclinical Data of Two ADC Programs at AACR 2025

PrimeLink to Present Preclinical Data of Two ADC Programs at AACR 2025

09 Apr,2025

MORE
< 12 >
免费热线

Tel:

0086 512-62652000

免费热线

E-mail:

hr@primelinkbio.com

地址

Add:

Building 4, Suhua Science Park , No.208 Tongyuan Road, Suzhou Industrial Park

Follow Us

©2022 PrimeLink BioTherapeutics  Powered by：CEglobal